Recent progress in advanced glycation end products and diabetic complications

Diabetes

Volumn 46, Issue SUPPL. 2, 1997, Pages

  Vlassara, Helen ^a  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; VERY LOW DENSITY LIPOPROTEIN;

AGING; ANIMAL TISSUE; ATHEROSCLEROSIS; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; GLYCATION; HUMAN; HUMAN TISSUE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 0030963670     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.2.s19     Document Type: Conference Paper

References (58)

1. Vlassara H, Bucala R, Striker L: Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. J Lab Invest 70:138-151, 1994
2. Dyer DG, Blackledge JA, Katz BM, Hull CJ, Adkisson HD, Thorpe SR, Lyons TJ, Baynes JW: The Maillard reaction in vivo. Z Ernahrugswiss 30:29-45, 1991
3. Bailey AJ, Sims TJ, Avery NC, Miles CA; Chemistry of collagen cross-links: glucose mediated covalent cross-linking of type-IV collagen in lens capsules. Biochem J 296:489-496, 1993
4. Dyer DG, Thorpe SR, Baynes JW: Formation of pentosidine during nonenzymatic browning of proteins by glucose-identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654-11660, 1991
5. Fu MX, Well-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW: Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43:676-683, 1994
6. Vlassara H, Bucala R: Advanced glycation and diabetes complications: an update. Diabetes Annual/Q 227-244, 1995
7. Nakamura K, Hasegawa T, Fukunaga Y, Lenaga K: Crosslines A and B as candidates for the fluorophores in age- and diabetes-related cross-linked proteins, and their diacetates produced by Maillard reaction of α-N-acetyl-L-lysine with D-glucose. J Chem Soc Chem Commun 992-994, 1992
8. Nakayama H, Taneda, S, Kuwajima S, Aoki S, Kuroda Y, Misawa K, Nakagawa S: Production and characterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 162:740-745, 1989
9. Horiuchi S, Araki N, Morino Y: Immunochemical approach to characterize advanced glycation endproducts of the Maillard reaction. J Biol Chem 266:7329-7332, 1991
10. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation endproducts in vivo. J Biol Chem 267:5133-5138, 1992
11. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 232:1629-1632, 1986
12. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90:6434-6438, 1993
13. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H: Modification of LDL by advanced glycosylation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445, 1994+
14. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87:432-438, 1991
15. de Tejada IS, Goldstein I, Azadzoi K, Krane RJ, Cohen RJR: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle in diabetic men with impotence. N Engl J Med 320:1025-1030, 1989
16. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR: Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:771-776, 1992
17. Gascho JA, Fanelli C, Zelis R: Aging reduces venous distensibiliry and the venodilatory response to nitroglycerin in normal subjects. Am J Cardiol 63:1267-1270, 1989
18. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R: Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 89:12043-12047, 1992
19. Hogan M, Cerami A, Bucala R: Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. J Clin Invest 790:1110-1115, 1992
20. Nicholls K, Mandel TE: Advanced glycosylation endproducts in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. J Lab Invest 60:486-491, 1989
21. Ellis EN, Good BH: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 40:1016-1019, 1991
22. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 40:1328-1334, 1991
23. Edelstein D, Brownlee M: Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35:96-97, 1992
24. Itakura M, Yoshikawa H, Bannai C, Kato M, Kunika K, Kawakami Y, Tamaoka T, Yamashita K: Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats. Life Sci 49:889-897, 1991
25. Cho HK, Kozu H, Peyman GA, Parry GJ, Khoobehi B: The effect of aminoguanidine on the blood-retinal barrier in streptozotocin-induced diabetic rats. Ophthalmic Surg 22:44-47, 1991
26. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555-11558, 1991
27. Hammes H-P, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K: Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37:32-35, 1994
28. Huijberts MSP, Wolffenbuttel BHR, Struijker-Boudier HAJ, Crijns FRL: Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 92:1407-1411, 1993
29. Huyberts MSP, Wolffenbuttel BHR, Crijns FRL, Nieuwenhuijzen Kruseman AC, Bemelmans MHA, Struijker Boudier HAJ: Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats. Diabetologia 37:10-14, 1994
30. Kihara J, Schmelzer JD, Podusio JF, Curran GL, Nickander KK, Low PA: Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 88:6107-6111, 1991
31. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K: Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41:47-52, 1992
32. Cameron NE, Cotter MA, Dines K, Love A: Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35:946-950, 1992
33. Odetti PR, Borgoglio A, De Pascale A, Rolandi R, Adezati L: Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 39:796-801, 1991
34. Oxlund H, Andreassen TT: Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus. Diabetologia 35:75-78, 1992
35. Makita Z, Vlassara H, Rayfleld E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R: Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 258:651-653, 1992
36. Vlassara H, Brownlee M, Cerami A: High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82:5588-5592, 1995
37. Vlassara H, Brownlee M, Cerami A; Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 164:1301-1309, 1996
38. Yang Z, Makita Z, Horii Y, Brunelle S, Cerami A, Sehajpal P, Suthanthiran M, Vlassara H: Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 174:515-524, 1991
39. Kelleher DJ, Kreibich G, Gilmore R: Oligosaccharyltransferase activity is associated with a protein complex composed of ribophorins I and II and a 48 kD protein. Cell 69:55-65, 1992
40. Silberstein S, Kelleher DJ, Gilmore R: The 48-kDa subunit of the mammalian Oligosaccharyltransferase complex is homologous to the essential yeast protein WBPI. J Biol Chem 267:23658-23663, 1992
41. Patel J, Kligman D: Purification and characterization of an M, 87,000 protein kinase C substrate from rat brain. J Biol Chem 262:16686-16691, 1997
42. Sakai K, Hirai M, Minoshima S, Kudoh J, Fukuyama R, Shimizu N: Isolation of cDNAs encoding a substrate for protein kinase C: nucleotide sequence and chromosomal mapping of the gene for a human 80K protein. Genomics 5:309-315, 1989
43. Imani F, Horii Y Suthanthiran M, Skolnik EY, Makita Z, Sharma V, Sehajpal, P Vlassara H: Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon-γ: role in tissue remodeling. J Exp Med 178:2165-2172, 1993
44. Libby P, Hansson GK: Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. J Lab Invest 64:5-15, 1991
45. Esposito C, Stern D, Gerlach H, Vlassara H: Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 170:1387-1407, 1989
46. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 256:14987-14997, 1992
47. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-15004, 1992
48. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, Migheli A, Stern D: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699-1712, 1993
49. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A: Identification of galectin-3 as a high affinity binding protein for advanced glycation endproducts (AGE), a new member of the AGE-receptor complex. Mol Med 1:634-646, 1995
50. Li YM, Tan AX, Vlassara H: Antibacterial activity of lysosyme and lactoferrin is inhibited by binding of advanced glycation-modifled proteins to a conserved motif. Nature Med 1:1057-1061, 1995
51. Vlassara H, Fuh H, Donnelly T, Cybulsky M: Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1:447-456, 1995
52. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ: Advanced glycosylation endproducts upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 91:9436-9440, 1994
53. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycosylation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91:11704-11708, 1994
54. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation endproducts in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
55. United States Renal Data System: USRDS 1992 Annual Data Report. Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, August 1992
56. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kauftnan AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, et al.: Reactive glycosylation endproducts in diabetic uraemia & treatment of renal failure. Lancet 343:1519-1522, 1994
57. 2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associate amyloidosis. J Clin Invest 92:1243-1252, 1993
58. 2-microglobulin modified with advanced glycation endproducts in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 93:521-527, 1994